year 18, Issue 72 And S12 (Supplement 12 2019)
J. Med. Plants 2019, 18(72 And S12): 64-77 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Maghsoumi F, Arbabi Bidgoli S. Hepatoprotective Effects of Curcumin Nanomicells in Alcohol-induced Liver Injury: Comparison with Curcumin and Silymarin in Mice Model. J. Med. Plants 2019; 18 (72) :64-77
URL: http://jmp.ir/article-1-2150-en.html
URL: http://jmp.ir/article-1-2150-en.html
1- Faculty of Pharmacy and Pharmaceutical Sciences, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
2- Department of Toxicology and Pharmacolgy, Faculty of Pharmacy and Pharmaceutical Sciences, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran ,sepideharbabi@gmail.com
2- Department of Toxicology and Pharmacolgy, Faculty of Pharmacy and Pharmaceutical Sciences, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran ,
Abstract: (4645 Views)
Background: Curcumin ameloriates liver damages but its poor absorption, rapid metabolism, and side effects at high doses may limit its clinical applications
Objective: This study aimed to evaluate the protective and regenerative effects of Curcumin Nanomicells on alcohol-induced chronic liver injuries in mice. These effects were compared with Curcumin and Silymarin in the same model.
Method: 42 female mice were divided to groups of normal control, alcoholic liver group, dose groups of NanoCurcumin with low (5 mg/kg), medium (50 mg/kg) and high (100 mg/kg) doses, Curcumin 100 mg/ kg and Silymarin 25 mg/kg, and monitored for 60 days. Results were analysed based on the serum levels of ALT, AST, ALP and LDH, and histopathological changes of the liver.
Results: Although the levels of liver enzymes were not significantly reduced in ethanol and NanoCurcumin group, the levels of ALT, AST significantly decreased in NanoCurcumin, Curcumin and Silymarin post treatment groups. Histopathological evidence confirmed the biochemical data which suggested the qualitative potentials of NanoCucumin in reducing alcohol-induced liver injuries. NanoCurcumin differentially reduced the LDH level, but the same effect was not detected in other treatment groups.
Conclusion: NanoCurcumin at 100 mg/kg/day can recover the chronic liver damages induced by alcohol and could reduce the LDH level, making it a possible candidate for future clinical application.
Objective: This study aimed to evaluate the protective and regenerative effects of Curcumin Nanomicells on alcohol-induced chronic liver injuries in mice. These effects were compared with Curcumin and Silymarin in the same model.
Method: 42 female mice were divided to groups of normal control, alcoholic liver group, dose groups of NanoCurcumin with low (5 mg/kg), medium (50 mg/kg) and high (100 mg/kg) doses, Curcumin 100 mg/ kg and Silymarin 25 mg/kg, and monitored for 60 days. Results were analysed based on the serum levels of ALT, AST, ALP and LDH, and histopathological changes of the liver.
Results: Although the levels of liver enzymes were not significantly reduced in ethanol and NanoCurcumin group, the levels of ALT, AST significantly decreased in NanoCurcumin, Curcumin and Silymarin post treatment groups. Histopathological evidence confirmed the biochemical data which suggested the qualitative potentials of NanoCucumin in reducing alcohol-induced liver injuries. NanoCurcumin differentially reduced the LDH level, but the same effect was not detected in other treatment groups.
Conclusion: NanoCurcumin at 100 mg/kg/day can recover the chronic liver damages induced by alcohol and could reduce the LDH level, making it a possible candidate for future clinical application.
Type of Study: Research |
Subject:
Pharmacology & Toxicology
Received: 2018/06/9 | Accepted: 2018/11/19 | Published: 2020/03/7
Received: 2018/06/9 | Accepted: 2018/11/19 | Published: 2020/03/7
References
1. Monton C, Charoenchai L, Suksaeree J and Sueree L. Quantitation of curcuminoid contents, dissolution profile, and volatile oil content of turmeric capsules produced at some secondary government hospitals. J. Food Drug Anal. 2016; 24 (3): 493 - 9. [DOI:10.1016/j.jfda.2016.01.007]
2. Lee W-H, Loo C-Y, Bebawy M, Luk F, Mason RS and Rohanizadeh R. Curcumin and its derivatives: their application in neuropharmacology and neuroscience in the 21st century. Curr. Neuropharmacol. 2013; 11 (4): 338 - 78. [DOI:10.2174/1570159X11311040002]
3. Girish C and Pradhan SC. Drug development for liver diseases: focus on picroliv, ellagic acid and curcumin. Fundam. Clin. Pharmacol. 2008; 22 (6): 623 - 32. [DOI:10.1111/j.1472-8206.2008.00618.x]
4. Wu P, Huang R, Xiong YL and Wu C. Protective effects of curcumin against liver fibrosis through modulating DNA methylation. Chin. J. Nat. Med. 2016; 14 (4): 255 - 64. [DOI:10.1016/S1875-5364(16)30025-5]
5. Yang K-Y, Lin L-C, Tseng T-Y, Wang S-C and Tsai T-H. Oral bioavailability of curcumin in rat and the herbal analysis from Curcuma longa by LC-MS/MS. J. Chromatogr B: Analyt. Technol. Biomed. Life Sci. 2007; 853 (1 - 2). 183-9. [DOI:10.1016/j.jchromb.2007.03.010]
6. Tønnesen HH, Másson M and Loftsson T. Studies of curcumin and curcuminoids. XXVII. Cyclodextrin complexation: solubility, chemical and photochemical stability. Int. J. Pharm. 2002; 244 (1 - 2): 127 - 35. [DOI:10.1016/S0378-5173(02)00323-X]
7. Jäger R, Lowery RP, Calvanese AV, Joy JM, Purpura M and Wilson JM. Comparative absorption of curcumin formulations. Nutr. J. 2014; 13: 11. [DOI:10.1186/1475-2891-13-11]
8. Lee WH, Loo CY, Young PM, Traini D, Mason RS and Rohanizadeh R. Recent advances in curcumin nanoformulation for cancer therapy. Expert Opin. Drug Deliv. 2014; 11 (8): 1183 - 201. [DOI:10.1517/17425247.2014.916686]
9. Yallapu MM, Jaggi M and Chauhan SC. Curcumin nanoformulations: a future nanomedicine for cancer. Drug Discov. Today 2012; 17 (1 - 2): 71 - 80. [DOI:10.1016/j.drudis.2011.09.009]
10. Song Z, Deaciuc I, Song M, Lee DYW, Liu Y, Ji X, and et al. Silymarin Protects Against Acute Ethanol‐Induced Hepatotoxicity in Mice. Alcohol. Clin. Exp. Res. 2006; 30 (3): 407 - 13. [DOI:10.1111/j.1530-0277.2006.00063.x]
11. Seitz HK, Lieber CS, Stickel F, Salaspuro M, Schlemmer HP and Horie Y. Alcoholic liver disease: from pathophysiology to therapy. Alcohol. Clin. Exp. Res. 2005; 29 (7): 1276 - 81. [DOI:10.1097/01.ALC.0000171896.37022.F7]
12. Seth D, Hogg PJ, Gorrell MD, McCaughan GW and Haber PS. Direct effects of alcohol on hepatic fibrinolytic balance: implications for alcoholic liver disease. J. Hepatol. 2008; 48 (4): 614 - 27. [DOI:10.1016/j.jhep.2007.12.015]
13. Barry R and McGivan J. Acetaldehyde alone may initiate hepatocellular damage in acute alcoholic liver disease. Gut. 1985; 26 (10): 1065 - 9. [DOI:10.1136/gut.26.10.1065]
14. Bertola A, Mathews S, Ki SH, Wang H and Gao B. Mouse model of chronic and binge ethanol Feeding (the NIAAA model). Nat. Protoc. 2013; 8 (3): 627 - 37. [DOI:10.1038/nprot.2013.032]
15. Abenavoli L, Izzo AA, Milić N, Cicala C, Santini A and Capasso R. Milk thistle (Silybum marianum): A concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases. Phytother. Res. 2018; 2202-2213. [DOI:10.1002/ptr.6171]
16. Clichici S, Olteanu D, Nagy AL, Oros A, Filip A and Mircea PA. Silymarin inhibits the progression of fibrosis in the early stages of liver injury in CCl₄-treated rats. J. Med. Food. 2015; 18 (3): 290 - 8. [DOI:10.1089/jmf.2013.0179]
17. Rabelo ACS, de Pádua Lúcio K, Araújo CM, de Araújo GR, de Amorim Miranda PH, Carneiro ACA, de Castro Ribeiro ÉM, de Melo Silva B, de Lima WG and Costa DC. Baccharis trimera protects against ethanol induced hepatotoxicity in vitro and in vivo. J. Ethnopharmacol. 2018; 215: 1 - 13. [DOI:10.1016/j.jep.2017.12.043]
18. Boyanapalli SSS, Huang Y, Su Z, Cheng D, Zhang C, Guo Y, Rao R, Androulakis IP and Kong AN. Pharmacokinetics and Pharmacodynamics of Curcumin in regulating anti-inflammatory and epigenetic gene expression. Biopharm. Drug Dispos. 2018; 39 (6): 289-297. [DOI:10.1002/bdd.2136]
19. Huang QH, Xu LQ, Liu YH, Wu JZ, Wu X, Lai XP, Li YC, Su ZR, Chen JN and Xie YL. Polydatin Protects Rat Liver against Ethanol-Induced Injury: Involvement of CYP2E1/ROS/Nrf2 and TLR4/NF-κB p65 Pathway. Evid Based Complement Alternat Med. 2017: 7953850. https://www.ncbi.nlm.nih.gov/pubmed. [DOI:10.1155/2017/7953850]
20. Joshi D, Mittal DK, Shukla S, Srivastav SK and Dixit VA. Curcuma longa Linn. extract and curcumin protect CYP 2E1 enzymatic activity against mercuric chloride-induced hepatotoxicity and oxidative stress: A protective approach. Exp. Toxicol. Pathol. 2017; 69: 373 - 82. [DOI:10.1016/j.etp.2017.02.009]
21. Fu Z, Chen X, Guan S, Yan Y, Lin H and Hua ZC. Curcumin inhibits angiogenesis and improves defective hematopoiesis induced by tumor-derived VEGF in tumor model through modulating VEGF-VEGFR2 signaling pathway. Oncotarget. 2015; 14; 6 (23): 19469 - 82. [DOI:10.18632/oncotarget.3625]
22. Fu Y, Zheng S, Lin J, Ryerse J and Chen A. Curcumin protects the rat liver from CCl4-caused injury and fibrogenesis by attenuating oxidative stress and suppressing inflammation. Mol. Pharmacol. 2008; 73 (2): 399 - 409. [DOI:10.1124/mol.107.039818]
23. Lin J and Chen A. Activation of peroxisome proliferator-activated receptor-γ by curcumin blocks the signaling pathways for PDGF and EGF in hepatic stellate cells. Lab. Invest. 2008; 88 (5): 529 - 40. [DOI:10.1038/labinvest.2008.20]
24. Hassan SK, Mousa AM, Eshak MG, Farrag A and Badawi A. Therapeutic and chemopreventive effects of nano curcumin against diethylnitrosamine induced hepatocellular carcinoma in rats. Int. J. Pharm. Pharm. Sci. 2014; 6 (3): 54.
25. Girish C, Koner BC, Jayanthi S, Ramachandra Rao K, Rajesh B and Pradhan SC. Hepatoprotective activity of picroliv, curcumin and ellagic acid compared to silymarin on paracetamol induced liver toxicity in mice. Fundam. Clin. Pharmacol. 2009; 23 (6): 735 - 45. [DOI:10.1111/j.1472-8206.2009.00722.x]
26. Sayrafi R, Hosseini S and Ahmadi M. The protective effects of nanocurcumin on liver toxicity induced by salinomycin in broiler chickens. Revue de Medecine Veterainare 2017; 168 (7 - 9): 136 - 42.
27. Mathews V, Binu P, Paul MS, Abhilash M, Manju A and Nair RH. Hepatoprotective efficacy of curcumin against arsenic trioxide toxicity. Asian Pac. J. Trop. Biomed. 2012; 2 (2): S706 - S11. [DOI:10.1016/S2221-1691(12)60300-1]
28. García-Niño WR and Pedraza-Chaverrí J. Protective effect of curcumin against heavy metals-induced liver damage. Food Chem. Toxicol. 2014; 69: 182 - 201. [DOI:10.1016/j.fct.2014.04.016]
29. Jurisic V, Radenkovic S and Konjevic G. The Actual Role of LDH as Tumor Marker, Biochemical and Clinical Aspects. Adv. Exp. Med. Biol. 2015; 867: 115 - 24. [DOI:10.1007/978-94-017-7215-0_8]
30. Faloppi L, Scartozzi M, Bianconi M, Svegliati Baroni G, Toniutto P, Giampieri R, Del Prete M, De Minicis S, Bitetto D, Loretelli C, D'Anzeo M, Benedetti A and Cascinu S. The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management. BMC Cancer. 2014; 14: 110. [DOI:10.1186/1471-2407-14-110]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
